Clinical Interchange: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno - Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder Cancers
WebcastFaculty
OVERVIEW
Clinical Interchange: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno - Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder Cancers is organized by Physicians Education Resource, LLC (PER) and will be held during Oct 31, 2017 - Oct 31, 2018.
The target audience for this medical event is directed toward medical oncologists and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals are also invited to participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Overview :
This Clinical Interchange features an expert panel discussion of noteworthy clinical data on immune checkpoint inhibitors. Practice-changing data and emerging immunotherapeutic strategies for cancers of the lung, head and neck, and bladder are summarized, along with expert discussions on the clinical application of these data and the evolving landscape of selective biomarkers. This program also includes a case-based discussion on the management of immune-related adverse events.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Explain clinically unmet needs in the management of non–small cell lung cancer, head and neck squamous cell carcinoma (HNSCC), and bladder cancer
• Describe how the immune system can be harnessed to treat cancer and the mechanistic rationale for the application of checkpoint inhibition strategies to target specific solid tumors
• Interpret recent findings from clinical trials conducted with immuno-oncology strategies for the treatment of lung cancer, HNSCC, and bladder cancer
• Describe the current status of biomarkers as a method to personalize care with the use of immuno-oncology strategies
• Evaluate methods to mitigate treatment-related toxicities via proactive mitigation and management of immune-related adverse events (irAEs)
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical oncologists and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals are also invited to participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Overview :
This Clinical Interchange features an expert panel discussion of noteworthy clinical data on immune checkpoint inhibitors. Practice-changing data and emerging immunotherapeutic strategies for cancers of the lung, head and neck, and bladder are summarized, along with expert discussions on the clinical application of these data and the evolving landscape of selective biomarkers. This program also includes a case-based discussion on the management of immune-related adverse events.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Explain clinically unmet needs in the management of non–small cell lung cancer, head and neck squamous cell carcinoma (HNSCC), and bladder cancer
• Describe how the immune system can be harnessed to treat cancer and the mechanistic rationale for the application of checkpoint inhibition strategies to target specific solid tumors
• Interpret recent findings from clinical trials conducted with immuno-oncology strategies for the treatment of lung cancer, HNSCC, and bladder cancer
• Describe the current status of biomarkers as a method to personalize care with the use of immuno-oncology strategies
• Evaluate methods to mitigate treatment-related toxicities via proactive mitigation and management of immune-related adverse events (irAEs)
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links